A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller…
Articles by Patricia Inacio, PhD
EastGate announced plans to expand its liquid insulin delivery platforms, used to treat type 2 diabetes, for use in a…
T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as…
Oligomannate (GV-971), a compound derived from marine brown algae that promotes a healthy gut microbiome, is now conditionally approved in…
Treatment with INmune Bio‘s lead candidate XPro1595 can help decrease neuroinflammation and amyloid beta accumulation triggered by a…
CareBand’s tracking bracelet, which pairs GPS technology to track movement and activity in real time, has been granted the…
Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in…
Athira Pharma has completed the Phase 1 trial testing NDX-1017, its lead therapeutic candidate for Alzheimer’s disease, and…
Therapeutics that target brain immune cells known as microglia may prevent the formation of amyloid-beta plaques, one of the…
Two global Phase 3 clinical trials — MISSION AD1 (NCT02956486) and MISSION AD2 (NCT03036280)…